Bli medlem
Bli medlem

Du är här

2016-01-14

Sanofi : Sanofi Pasteur Provides Key Support to the Human Vaccines Project

Sanofi Pasteur Provides Key Support to the Human Vaccines Project

- The research program is designed to accelerate the development of vaccines
by decoding the human immune system -

Lyon, France - January 14, 2015 -
Sanofi Pasteur, the vaccines division ofSanofi, has signed an agreement with
the Human Vaccines Project Inc. to partially fund the non-profit,
public-private partnership convening leading academic researchers and
industrial partners to solve the primary problems impeding
vaccine/immunotherapy development by "decoding" the human immune system. The
Project is a global consortium.

Sanofi Pasteur is supporting the Project by providing research funding to
oversee, coordinate and conduct the scientific and administrative activities
of the Human Vaccines Project Research Program this year. The funds will be
used by the Project to launch and execute pilot studies, build partnerships
with and across the stakeholder community, and set up the infrastructure and
operational support for the Human Vaccines Project Research Program.

The Project, which has been endorsed as potentially transformative by 35 of
the world's leading vaccine scientists, seeks to raise $1 billion over a
decade. The Project was incubated at the International AIDS Vaccine
Initiative (IAVI) and is supported by leading academic research centers,
industrial partners, and nonprofits to address the primary scientific
barriers to developing new vaccines and immunotherapies.

"Sanofi Pasteur is proud to join this effort to accelerate and transform
vaccine development for major and emerging infectious diseases as well as to
better understand human immunology, which may be applicable toward disease
management of other chronic disease states,"
commented Jim Tartaglia, PhD, Sanofi Pasteur's R&D Vice President for New
Vaccine Projects."The Project's partnerships with industrial and non-profit
product developers
are key to ensuring that technological breakthroughs are rapidly translated
into new products."

As a member of the Industry Advisory Committee, Sanofi Pasteur will provide
input on the Human Vaccines Project Research Program, review both published
and unpublished data, and participate at various scientific workshops to be
held by the Project. Sanofi Pasteur will be represented by R&D Vice President
for Translational Science&Biomarkers Kent Kester, M.D.

"A better understanding of human immunity holds the key to accelerating the
vaccine and immunotherapy development for complex global diseases such as
HIV, tuberculosis, emerging infectious diseases and cancers,"
according to Dr. Kester."And since vaccines are among the greatest successes
in the history of public
health, having led to the eradication of smallpox, near eradication of polio,
prevention of 2-3 million deaths per year, and dramatic reductions in human
suffering and healthcare costs, the Project makes sense for all of us,"
he continued.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
((EURONEXT:SAN) and in New York (NYSE:SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion
doses of vaccine each year, making it possible to immunize more than 500
million people across the globe. A world leader in the vaccine industry,
Sanofi Pasteur offers a broad range of vaccines protecting against 20
infectious diseases. The company's heritage, to create vaccines that protect
life, dates back more than a century. Sanofi Pasteur is the largest company
entirely dedicated to vaccines. Every day, the company invests more than EUR
1 million in research and development. For more information, please
visit:www.sanofipasteur.comorwww.sanofipasteur.us

Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.

--------------------------------------------------------------------
| Contacts: |
| |
| Global Media Relations U.S. Media Relations |
| |
| |
|Alain Bernal Susan Watkins |
|T. +33-4-37-37-50-38 T. +570-957-2563 |
|alain.bernal@sanofipasteur.com susan.watkins@sanofipasteur.com |
| |
|www.sanofipasteur.com www.sanofipasteur.com |
| |
| Investor Relations |
| |
|Sébastien Martel |
|T. + 33 1 53 77 45 45 |
|ir@sanofi.com |
| |
| |
| |
--------------------------------------------------------------------
Press release
http://hugin.info/152918/R/1976845/724544.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#1976845

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.